Table 2.
Participants characteristics and viral suppression levels.
| Variable | Overall† N = 9034 | < 50 copies/mL‡ N = 6840 (75.7%) | 50–999 copies/mL‡ N = 1272 (14.1%) | < 1000 copies/mL‡ N = 8112 (89.8%) | ≥ 1000 copies/mL‡ N = 922 (10.2%) | P value* |
|---|---|---|---|---|---|---|
| Gender, n (%) | ||||||
| Male | 2508 (27.8) | 1758 (70.1) | 425 (16.9) | 2183 (87.0) | 325 (13.0) | P < .0001 |
| Female | 6526 (72.2) | 5082 (77.9) | 847 (13.0) | 5929 (90.9) | 597 (9.1) | |
| Age in yr, median (IQR) | 39 (32–48) | 40 (32–48) | 39 (31–48) | 40 (32–48) | 37 (27–45) | P < .0001 |
| Age groups, n (%) | ||||||
| Children | 222 (2.5) | 104 (46.8) | 40 (18.0) | 144 (64.9) | 78 (35.1) | P < .0001 |
| Adolescents | 227 (2.5) | 138 (60.8) | 31 (13.7) | 169 (74.4) | 58 (25.5) | |
| Adults | 8585 (95.0) | 6598 (76.9) | 1201 (14.0) | 7799 (90.8) | 786 (9.1) | |
| Duration on cART in month, median (IQR) | 24 (12–72) | 24 (12–72) | 12 (12–60) | 18 (12–66) | 24 (12–72) | P < .0001 |
| Duration on cART in mo | ||||||
| 6–12 | 4013 (44.4) | 2957 (73.7) | 669 (16.7) | 3626 (90.4) | 387 (9.6) | P < .0001 |
| 13–24 | 655 (7.3) | 478 (73.0) | 96 (14.7) | 574 (87.6) | 81 (12.4) | |
| 25–36 | 672 (7.4) | 501 (74.6) | 90 (13.4) | 591 (87.9) | 81 (12.1) | |
| ≥48 | 3694 (40.9) | 2904 (78.6) | 417 (11.3) | 3321 (89.9) | 373 (10.1) | |
| ART combination, n (%) | ||||||
| TDF + 3TC + DTG | 7117 (78.8) | 5538 (77.8) | 995 (14.0) | 6533 (91.8) | 584 (8.2) | P < .0001 |
| Other 1st line ARV | 1627 (18.0) | 1180 (72.5) | 226 (13.9) | 1406 (86.4) | 221 (13.6) | |
| ATVr or LPVr based ARV | 290 (3.2) | 122 (42.1) | 51 (17.6) | 173 (59.7) | 117 (40.3) | |
3TC = lamivudine, ART = antiretroviral therapy, ARV = antiretroviral, ATVr = ritonavir boosted atazanavir, cART = combined antiretroviral therapy, DTG = dolutegravir, EFV = efavirenz, IQR = interquartile range, LPVr = ritonavir boosted lopinavir, TDF = tenofovir disoproxil fumarate.
Other first-line ARV [ABC + 3TC + EFV (n = 13), ABC + 3TC + NVP (n = 2), AZT + 3TC + EFV (n = 36), AZT + 3TC + NVP (n = 14), TDF + 3TC + NVP (n = 51), TDF + 3TC + EFV (1511)], Lopinavir based (n = 173) and atazanavir based (n = 117).
*
P value for virological success at < 1000 copies/M.
†
Percentages in this column represent column percentage.
‡
Percentages in this column represents row percentage.